Glaucoma research focuses on neurodegeneration

Article

The growing understanding that glaucoma is a neurodegenerative rather than ocular disease is to be the principal topic of discussion of the annual Glaucoma Research Foundation (GRF) benefit, to be held January 28 2009 in San Francisco, California, US.

The growing understanding that glaucoma is a neurodegenerative rather than ocular disease is to be the principal topic of discussion of the annual Glaucoma Research Foundation (GRF) benefit, to be held 28 January 2009 in San Francisco, California, US. The Catalyst For a Cure (CFC) research consortium, composed of neuroscientists and geneticists, will present a Research Overview of the notable breakthroughs made in 2008.

CFC research has this year established that oxidative stress affects the rate of glaucomatous cellular function loss, and that neuronal loss due to glaucoma is preceded by degeneration of the axons, indicating that glaucoma can be predicted by observing changes to genes and proteins. The CFC is now concentrating on studying general features of neurodegeneration in the hope of discovering a therapeutic or interventional treatment to arrest or the development or reverse the progression of glaucoma.

During the benefit, Rohit Varma, MD of the University of Southern California will receive the President's Award and H. Dunbar Hoskins Jr., MD, executive vice president of the American Academy of Ophthalmology, will be presented with the GRF's highest honour, The Catalyst Award.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.